Buccal Drug Delivery System Market Overview, Analysis And Demand By 2034

Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors

What Is the Forecasted Market Size of the Buccal Drug Delivery System Market by 2029?
The buccal drug delivery system market size has grown strongly in recent years. It will grow from $3.55 billion in 2024 to $3.89 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to early drug delivery innovations, pharmaceutical industry adoption, clinical studies and efficacy, market penetration strategies, disease-specific applications.

The buccal drug delivery system market size is expected to see rapid growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to patient-centric drug delivery, rising geriatric population, demand for targeted therapies, biologics and peptides delivery, regulatory support and approvals, investments in r&d. Major trends in the forecast period include patient convenience and compliance, advancements in drug formulations, rise in chronic diseases, pediatric and geriatric care, enhanced bioavailability.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

Which Factors Are Driving Growth in the Buccal Drug Delivery System Market?
The rising prevalence of chronic diseases is expected to propel the growth of the buccal drug delivery systems market going forward. Chronic diseases refer to ailments that persist for a year or longer, such as cancer, heart disease, stroke, diabetes, cancer, and arthritis. These are the most prevalent chronic illnesses that can be managed but not cured and necessitate continuous nutrition and medical care. Buccal drug delivery systems provide appropriate and effective drug delivery for administering mucosal and transmucosal drugs that are required by several patients suffering from chronic diseases such as diabetes and cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases drives the growth of the buccal drug delivery systems market.

What Are the Key Segments in the Buccal Drug Delivery System Market?
The buccal drug delivery systemmarket covered in this report is segmented –

1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays
2) By Application: Pain Management, Smoking Cessation, Angina Pectoris
3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

Subsegments:
1) By Sublingual: Sublingual Tablets, Sublingual Films
2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges
3) By Oral Sprays: Spray Solutions, Spray Gels

Which Emerging Trends Are Driving the Buccal Drug Delivery System Market?
Major companies operating in the buccal drug delivery systems market are focusing on developing innovative solutions, such as oral treatment for plaque psoriasis, to improve patient outcomes and enhance the efficacy of drug delivery. Oral treatment for plaque psoriasis refers to the administration of medications taken by mouth to manage and alleviate the symptoms of plaque psoriasis, a chronic autoimmune condition characterized by the rapid growth of skin cells leading to thick, red, scaly patches. For instance, in September 2022, Bristol Myers Squibb, a US-based pharmaceutical industry company, received FDA approval for Sotyktu (deucravacitinib), an oral treatment for adults with moderate-to-severe plaque psoriasis. This approval marks the first new oral therapy for this condition in nearly a decade, offering a novel mechanism of action as a selective inhibitor of tyrosine kinase 2 (TYK2).

Who Are the Leading Players in the Buccal Drug Delivery System Market?
Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.

Get the full buccal drug delivery system market report here:
https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

What Are the Key Regional Trends in the Buccal Drug Delivery System Market?
North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company